Oral Vaccination Through Peyer's Patches: Update on Particle Uptake

Soares, Edna; Borges, Fernandes

doi:10.2174/1567201814666170825153955

Cited by 12 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microparticles constructed of chitosan have also been investigated, as chitosan has immunostimulating properties in its own right, because of its polycationic nature [91]. For comprehensive reviews of the performance of polymeric particles in disease models see references [92,93].…”

Section: Polymeric Particulatesmentioning

confidence: 99%

Formulation technologies for oral vaccines

New

2019

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Summary Many options now exist for constructing oral vaccines which, in experimental systems, have shown themselves to be able to generate highly effective immunity against infectious diseases. Their suitability for implementation in clinical practice, however, for prevention of outbreaks, particularly in low‐ and middle‐income countries (LMIC), is not always guaranteed, because of factors such as cost, logistics and cultural and environmental conditions. This brief overview provides a summary of the various approaches which can be adopted, and evaluates them from a pharmaceutical point, taking into account potential regulatory issues, expense, manufacturing complexity, etc., all of which can determine whether a vaccine approach will be successful in the late stages of development. Attention is also drawn to problems arising from inadequate diet, which impacts upon success in stimulating effective immunity, and identifies the use of lipid‐based carriers as a way to counteract the problem of nutritional deficiencies in vaccination campaigns.

show abstract

Section: Polymeric Particulatesmentioning

confidence: 99%

Formulation technologies for oral vaccines

New

2019

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Oral administration represents an interesting strategy in terms of ease of delivery, patient compliance, and safety ( 39 ). However, due to the intrinsic high dilution of vaccine formulations and the harsh environment of the digestive tract, substantial amounts of Ags have to be administered.…”

Section: Vaccine Sampling At Mucosal Surfaces and The Selection Of Thmentioning

confidence: 99%

Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection

Corthésy

Bioley

2018

Front. Immunol.

View full text Add to dashboard Cite

Vaccination is the process of administering immunogenic formulations in order to induce or harness antigen (Ag)-specific antibody and T cell responses in order to protect against infections. Important successes have been obtained in protecting individuals against many deleterious pathological situations after parenteral vaccination. However, one of the major limitations of the current vaccination strategies is the administration route that may not be optimal for the induction of immunity at the site of pathogen entry, i.e., mucosal surfaces. It is now well documented that immune responses along the genital, respiratory, or gastrointestinal tracts have to be elicited locally to ensure efficient trafficking of effector and memory B and T cells to mucosal tissues. Moreover, needle-free mucosal delivery of vaccines is advantageous in terms of safety, compliance, and ease of administration. However, the quest for mucosal vaccines is challenging due to (1) the fact that Ag sampling has to be performed across the epithelium through a relatively limited number of portals of entry; (2) the deleterious acidic and proteolytic environment of the mucosae that affect the stability, integrity, and retention time of the applied Ags; and (3) the tolerogenic environment of mucosae, which requires the addition of adjuvants to elicit efficient effector immune responses. Until now, only few mucosally applicable vaccine formulations have been developed and successfully tested. In animal models and clinical trials, the use of lipidic structures such as liposomes, virosomes, immune stimulating complexes, gas-filled microbubbles and emulsions has proven efficient for the mucosal delivery of associated Ags and the induction of local and systemic immune reponses. Such particles are suitable for mucosal delivery because they protect the associated payload from degradation and deliver concentrated amounts of Ags via specialized sampling cells (microfold cells) within the mucosal epithelium to underlying antigen-presenting cells. The review aims at summarizing recent development in the field of mucosal vaccination using lipid-based particles. The modularity ensured by tailoring the lipidic design and content of particles, and their known safety as already established in humans, make the continuing appraisal of these vaccine candidates a promising development in the field of targeted mucosal vaccination.

show abstract

“…Approximately, half of particles that deposit in ciliated airways will undergo mucociliary clearance within 24 h, whereby particles are cleared from the lung, swallowed, and potentially encounter phagocytic cells in gutassociated lymphoid tissue (Lippmann and Albert, 1969;Pais Soares and Fernandes Borges, 2018). Particles that remain in airways can form chain-aggregates and may accumulate in airway and interstitial macrophages, bronchial epithelial cells, or pulmonary fibroblasts (Bai et al, 2018;Brauer et al, 2001;Belade et al, 2012;Geiser, 2002).…”

Section: Introductionmentioning

confidence: 99%

Black carbon accumulation in extrapulmonary human tissues

Florsheim¹,

Bressler²,

Tsai³

et al. 2021

J. Toxicol. Environ. Health Sci.

View full text Add to dashboard Cite

Black carbon is a product of incomplete combustion and is associated with a number of adverse health outcomes in epidemiologic studies. To date, anatomic studies investigating the pathogenic mechanisms of black carbon in humans have confirmed black carbon particles accumulate in the lung and in the placenta of pregnant women, and are excreted in urine. In this feasibility study, the presence of black carbon particles was demonstrated in post-mortem spleen, myocardium, and hilar lymph node samples obtained from three de-identified sources. A protocol validated for extraction of chemically inert particles from fish tissue was utilized to extract black carbon particles from human tissue. Visual examination and micro-Raman scattering spectroscopy were used to identify recovered black carbon particles. Recovered particles ranged from 2 to 45 m in greatest dimension. The highest concentrations of black carbon particles were recovered from hilar lymph nodes, followed by the myocardium, with lowest concentrations recovered from the spleen. Particles extracted from the spleen were, on average, larger than particles extracted from the heart or hilar lymph nodes. These findings confirm black carbon particles accumulate in human extrapulmonary organs. Based on the size and concentrations of recovered particles, it is suggested that black carbon particles are transported to extrapulmonary sites via the lymphatic system. Furthermore, the noted concentration differentials suggest reduced black carbon particle clearance from the myocardium compared with the spleen.

show abstract

Oral Vaccination Through Peyer's Patches: Update on Particle Uptake

Abstract: We provide a short and concise update (last decade) focused on the importance of particle physicochemical properties, M-cell ligands and size-dependent transport and intracellular fate concerning Peyer's patches targeted oral vaccination.

Cited by 12 publications

References 0 publications

Formulation technologies for oral vaccines

Formulation technologies for oral vaccines

Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection

Black carbon accumulation in extrapulmonary human tissues

Contact Info

Product

Resources

About